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BACKGROUND
The use of remote monitoring (RM) of
pacemakers is limited, and very few studies have
focused on their comparative effectiveness.
OBJECTIVES
RESULTS
Evaluate the effectiveness of RM of pacemakers
Controlled, not randomized nor masked clinical trial, with collecting data pre and post-implantation and a follow-up of 6 months. All patients over 18 who were implanted a PM in the study period were selected (n=83), being assigned either to RM (n=30) or to HM (n=53) group. Baseline characteristics and number of visits to the hospital were analysed, and the questionnaires administrated were EuroQol-5D (EQ5D) to evaluate the health-related quality of life and Duke Activity Status Index (DASI) to assess the functional capacity.
Controlled, not randomized nor masked clinical trial,
with collecting data pre and post-implantation and a
follow-up of 6 months. All patients over 18 who were
implanted a pacemakers in the study period were
selected (n=83), being assigned either to RM (n=30)
or to HM (n=53) group. Baseline characteristics and
number of visits to the hospital were analysed, and
the questionnaires administrated were EuroQol-5D
(EQ5D) to evaluate the health-related quality of life
METHODS
Groups were similar in baseline characteristics, including EQ5D
(RM:0,7299; HM:0,6769) and DASI (RM:21,41; HM:19,99). At 6 months,
EQ5D was improved in both groups (EQ5D RM:0,8613; HM:0,8175;
p=0,439) still without significant differences between them. DASI score
was similar to baseline. Significant differences were found in number of
follow-up transmissions/visits per patient, being lower for RM group
(1.57 vs. 1.96; relative reduction 31%; p=0.015).
CONCLUSIONS
Although remote monitoring of
pacemakers shows a similar
effectiveness and safety, it
significantly reduces the
number of follow-up visits
regarding hospital monitoring.
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in comparison with the monitoring performed in
hospital (HM). and Duke Activity Status Index (DASI) to assess the
functional capacity.
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PATIENT SELECTION
Patients were included in the study if they had
been implanted with a single [VVI-VVIR] or
double chamber [VDD-DDD] Medtronic Carelink®
pacemakers within the past 18 years, if they were
capable of understanding and correctly
performing the home auto-monitoring or had a
caregiver who could carry out this function, and is
they agreed to participate in the study by signing
the informed consent. Patients were excluded if
they had been enrolled in another study, if they
had any other cardiac device or if they refused to
participate.
ETHICAL CONSIDERATION
The Almeria Health Research Ethical Committee
approved the trial protocol and the study was
developed in accordance with the precepts of the
Declaration of Helsinki and Spanish laws on data
protection and patient rights. All patients signed the
corresponding informed consent prior to their
enrolment, and appropriate measures were taken to
ensure data privacy.
The trial protocol was registered in ClinicalTrials.gov
(Identifier: NCT02234245).
Mean 95% CI Mean 95% CI P
EQ5D (Utilities) 0.86 0.77 – 0.95 0,82 0,75 – 0,89 0,44
EQ5D (VAS) 69,50 64,89 - 74,10 68,30 64,78 - 71,81 0,68
DASI 23,10 21,20 - 25,10 21,07 19,50 - 22,60 0,10
EQ5D: EuroQoL-5D; VAS: VISUAL ANALOGUE SCALE; DASI: Duke Activity
Status Index
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